Drug Type Small molecule drug |
Synonyms J2H 1802, J2H-1802 |
Target |
Action inhibitors, stimulants |
Mechanism NF-κB inhibitors(Nuclear factor NF-kappa-B complex inhibitors), Nrf2 stimulants(Nuclear factor erythroid 2-related factor 2 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Inflammatory Bowel Diseases | Preclinical | South Korea | 01 Jul 2026 | |
| Psoriasis | Preclinical | South Korea | 01 Feb 2023 |





